Evidence map›Paper›PMID 40452015›Full record

ArticleBMC cancer2025

Cholesterol-induced colorectal cancer progression and its mitigation through gut microbiota remodeling and simvastatin treatment.

Xiaoliang Xie, Wenjing Wang, Haiming Zhang, Shaohui Zhao, Na Zhang, Ying Gao, Quanxia Liu, Xiaomei Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Cholesterol as a metabolic integrator of oncogenic signaling, immune evasion, and therapy resistance.Apoptosis : an international journal on programmed cell death · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xiaoliang Xie *Department of Colorectal Surgery, General Hospital of Ningxia Medical University, Yinchuan, 750004, China.
Wenjing Wang *Ningxia Medical University, Yinchuan, 750004, China.
Haiming ZhangNingxia Medical University, Yinchuan, 750004, China.
Shaohui ZhaoNingxia Medical University, Yinchuan, 750004, China.
Na ZhangDepartment of Obstetrics and Gynecology, Ningxia Hui Autonomous Region People's Hospital, Yinchuan, 750004, China.
Ying GaoDepartment of Oncology, People's Hospital of Ningxia Hui Autonomous Region, Yinchuan, Ningxia, China.
Quanxia LiuThe Second Department of Oncology, Ningxia Medical University General Hospital, Yinchuan, 750004, China. doctorliuqx@163.com.
Xiaomei ChenDepartment of Geriatrics, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China. 18080407013@163.com.

Funding

Ningxia Key R&D Program 2023BEGO3038Ningxia Natural Science Foundation 2024AAC03686
6 · The paper itself

Abstract

backgroundElevated serum cholesterol levels are linked to an increased risk of colorectal adenomas and colorectal cancer (CRC), yet the role of serum low-density lipoprotein (LDL) in CRC development remains unclear. This study explores the impact of cholesterol on tumor growth and the potential therapeutic effects of Lactobacillus and Simvastatin.

methodsWe utilized a cecal tumor xenograft mouse model with Ldlr

resultsLdlr

conclusionElevated serum cholesterol promotes CRC progression, while gut microbiota remodeling through Lactobacillus supplementation and cholesterol-lowering interventions, such as Simvastatin, show potential in mitigating tumor growth and enhancing antitumor immune responses. These findings highlight the importance of cholesterol management in CRC treatment strategies.

Indexed as

CholesterolColorectal NeoplasmsGastrointestinal MicrobiomeSimvastatinAnimalsCell Line, TumorCell ProliferationDisease Models, AnimalDisease ProgressionHumansLactobacillusMaleMiceMice, KnockoutReceptors, LDLTumor MicroenvironmentCholesterolReceptors, LDLSimvastatinColorectal cancerGut microbiotaLactobacillusLow-density lipoproteinSimvastatin

Identifiers

PMID40452015
PMCPMC12128496

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.